UK Markets closed

Apontis Pharma AG (APPH.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
9.10-0.28 (-2.99%)
At close: 03:01PM CET

Apontis Pharma AG

Alfred-Nobel-Str. 10
Monheim am Rhein 40789
49 2173 8955 4949

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees127

Key executives

NameTitlePayExercisedYear born
Mr. Karlheinz GastChairman of the Management Board & CEON/AN/AN/A
Mr. Thomas MilzChief Product Officer & Deputy Chairman of Management BoardN/AN/AN/A
Mr. Thomas ZimmermannChief Financial OfficerN/AN/AN/A
Mr. Harald WeyandHead of MarketingN/AN/AN/A
Dr. Matthias WendlHead of SalesN/AN/AN/A
Ms. Susanne BöhmHead of HRN/AN/AN/A
Dr. Olaf RanderathHead of MedicineN/AN/AN/A
Dr. Susanne EndreßHead of QA, Drug Safety & Regulatory AffairsN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company is headquartered in Monheim am Rhein, Germany.

Corporate governance

Apontis Pharma AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.